Vera Therapeutics (VERA) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free VERA Stock Alerts $37.13 +0.02 (+0.05%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 1:20 PM | markets.businessinsider.comVera Therapeutics Says FDA Grants Breakthrough Therapy Designation For Atacicept To Treat IgANMay 28 at 11:48 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up to $37.11Vera Therapeutics (NASDAQ:VERA) Shares Gap Up to $37.11May 28 at 8:00 AM | globenewswire.comVera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)May 26 at 3:40 AM | americanbankingnews.comVera Therapeutics (NASDAQ:VERA) Shares Up 5.3%May 25, 2024 | globenewswire.comVera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association CongressMay 24, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading 5.3% Higher Vera Therapeutics (NASDAQ:VERA) Shares Up 5.3%May 20, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down to $41.39Vera Therapeutics (NASDAQ:VERA) Shares Gap Down to $41.39May 16, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have earned a consensus rating of "Buy" from the eight analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one hasMay 13, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Down 1.9% Vera Therapeutics (NASDAQ:VERA) Trading Down 1.9%May 10, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Issues Earnings ResultsVera Therapeutics (NASDAQ:VERA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.03).May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vera Therapeutics Amid Promising Clinical Developments and Strong Financial PositionMay 9, 2024 | investorplace.comVERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024May 9, 2024 | msn.comVera Therapeutics GAAP EPS of -$0.56May 9, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | globenewswire.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | finance.yahoo.comVera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last weekMay 2, 2024 | markets.businessinsider.comIncyte’s Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales DipMay 1, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading 6.5% Higher Vera Therapeutics (NASDAQ:VERA) Trading Up 6.5%April 15, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Down 3% After Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Down 3% Following Insider SellingApril 14, 2024 | investing.comVera Therapeutics executive sells over $228k in company stockApril 14, 2024 | marketbeat.comVanguard Group Inc. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Vanguard Group Inc. raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 9.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,574,390 shares of the company's stock after puApril 13, 2024 | insidertrades.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of StockApril 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | finance.yahoo.comInsider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...April 12, 2024 | marketbeat.comJoseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) SVP Joseph R. Young sold 5,714 shares of the company's stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total value of $228,560.00. Following the sale, the senior vice president now owns 53,171 shares in the company, valued at approximately $2,126,840. The sale was disclosed in a filing with the SEC, which is available through the SEC website.April 11, 2024 | msn.comBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 10, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%April 10, 2024 | msn.comAlpine Immune jumps on report of takeover interestApril 8, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider SellingApril 8, 2024 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in StockApril 7, 2024 | nasdaq.comCommit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using OptionsApril 6, 2024 | marketbeat.comSean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CFO Sean Grant sold 99,828 shares of the business's stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total value of $3,954,187.08. Following the completion of the sale, the chief financial officer now owns 66,337 shares in the company, valued at $2,627,608.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.April 5, 2024 | marketbeat.comGuggenheim Reiterates Buy Rating for Vera Therapeutics (NASDAQ:VERA)Guggenheim reiterated a "buy" rating and set a $56.00 price objective on shares of Vera Therapeutics in a research note on Friday.April 3, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Down 5.9% Vera Therapeutics (NASDAQ:VERA) Shares Down 5.9%April 3, 2024 | seekingalpha.comVera Therapeutics: Waiting For A PullbackMarch 29, 2024 | marketbeat.comWellington Management Group LLP Takes $1.16 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Wellington Management Group LLP bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 84,506 shares of the company's stock, valued atMarch 27, 2024 | marketbeat.comGuggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $56.00Guggenheim boosted their target price on Vera Therapeutics from $27.00 to $56.00 and gave the stock a "buy" rating in a research report on Wednesday.March 26, 2024 | finanznachrichten.deProtagonist Therapeutics, Inc.: Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line DataMarch 26, 2024 | insidertrades.comInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Sells 340,000 Shares of StockMarch 26, 2024 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Maha Katabi Sells 81,009 SharesMarch 21, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading Down 7%Vera Therapeutics (NASDAQ:VERA) Stock Price Down 7%March 21, 2024 | marketbeat.comVera Therapeutics (NASDAQ:VERA) PT Raised to $34.00Wedbush boosted their price target on Vera Therapeutics from $21.00 to $34.00 and gave the stock a "neutral" rating in a research report on Thursday.March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Vera Therapeutics Ahead of Key Atacicept Clinical MilestonesMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vera Therapeutics with Promising Trials and Strong Financial RunwayMarch 20, 2024 | benzinga.comVera Therapeutics: Q4 Earnings InsightsMarch 20, 2024 | msn.comVera Therapeutics GAAP EPS of -$2.25 misses by $0.07March 20, 2024 | investorplace.comVERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023March 20, 2024 | globenewswire.comVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | marketbeat.comCitigroup Inc. Buys 47,322 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Citigroup Inc. lifted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 470.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,390 shares of the company's stock after purchasing anMarch 17, 2024 | bbc.co.ukWeekend Woman’s Hour: Irish folk singer Cara Dillon, The Hampstead Paedophile Hoax, Maximalism Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race… Click here to see a unique election-year trade VERA Media Mentions By Week VERA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.720.86▲Average Medical News Sentiment VERA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼83▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Geron News Today Deciphera Pharmaceuticals News Today Amneal Pharmaceuticals News Today Amphastar Pharmaceuticals News Today Rhythm Pharmaceuticals News Today Rocket Pharmaceuticals News Today Indivior News Today Zai Lab News Today Arvinas News Today Catalyst Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.